ReviewBone research2015
Parathyroid hormone pulsatility: physiological and clinical aspects.
Review in Bone research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 53 citations in OpenAlex.
- Defining the potential role of the mineralocorticoid receptor in musculoskeletal health and bone crosstalk with other tissues.The Journal of endocrinology · 2026Review
- Teriparatide in Two Patients With Mucopolysaccharidosis Type IVB.JIMD reports · 2026Article
- Calculation of postoperative parathyroid hormone level using indocyanine green angiography during robotic total thyroidectomy: equivalent function hypothesis.Surgical endoscopy · 2026Article
- Pulsatile Release of Human Gonadotropin Releasing Hormone Using a Photoactivated Depot Containing an Unusual Light Cleaved Functionality.Molecular pharmaceutics · 2026Article
- Nutritional adaptation to circadian misalignment: implications for musculoskeletal health in modern lifestyles.Frontiers in nutrition · 2026Review
- Parathyroid hormone receptor agonists in the management of osteoporosis.Nature reviews. Rheumatology · 2025Review
- The Chronobiology of Hormone Administration: "Doctor, What Time Should I Take My Medication?"Endocrine reviews · 2025Review
- Serum 25-Hydroxyvitamin D and Intact Parathyroid Hormone as Functional Biomarkers of Bone Mass in Early Childhood.The Journal of nutrition · 2025Observational
- Indocyanine green angiography to evaluate immediate hypoparathyroidism after thyroid cancer surgery.Endocrine · 2025Article
- Computational simulations of endocrine bone diseases related to pathological glandular PTH secretion using a multi-scale bone cell population model.Frontiers in bioengineering and biotechnology · 2025Article
- Association between tobacco smoke exposure and serum parathyroid hormone levels among US adults (NHANES 2003-2006).Scientific reports · 2024Article
- Injective hydrogel loaded with liposomes-encapsulated MY-1 promotes wound healing and increases tensile strength by accelerating fibroblast migration via the PI3K/AKT-Rac1 signaling pathway.Journal of nanobiotechnology · 2024Article
- Human Parathyroid Hormone Analog (3-34/29-34) promotes wound re-epithelialization through inducing keratinocyte migration and epithelial-mesenchymal transition via PTHR1-PI3K/AKT activation.Cell communication and signaling : CCS · 2023Article
- Effect of Circadian Rhythm Disturbance on the Human Musculoskeletal System and the Importance of Nutritional Strategies.Nutrients · 2023Review
- Skeletal complications in acromegaly.Reumatologia · 2023Review
- Article
- Skeletal disorders associated with the growth hormone-insulin-like growth factor 1 axis.Nature reviews. Endocrinology · 2022Review
- Hypovitaminosis D and the endocrine phenotype of COVID-19.Endocrine · 2021Review
- Influence of medication and PTH levels on detection of parathyroid adenomas with dual isotope parathyroid scintigraphy.American journal of nuclear medicine and molecular imaging · 2021Article
- The Physiology of Reproduction -Frontiers in physiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parathyroid hormone (PTH) secretion is characterized by an ultradian rhythm with tonic and pulsatile components. In healthy subjects, the majority of PTH is secreted in tonic fashion, whereas approximately 30% is secreted in low-amplitude and high-frequency bursts occurring every 10-20 min, superimposed on tonic secretion. Changes in the ultradian PTH secretion were shown to occur in patients with primary and secondary osteoporosis, with skeletal effects depending on the reciprocal modifications of pulsatile and tonic components. Indeed, pathophysiology of spontaneous PTH secretion remains an area potentially suitable to be explored, particularly in those conditions such as secondary forms of osteoporosis, in which conventional biochemical and densitometric parameters may not always give reliable diagnostic and therapeutic indications. This review will highlight the literature data supporting the hypothesis that changes of ultradian PTH secretion may be correlated with skeletal fragility in primary and secondary osteoporosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.